targeted DEP-trastuzumab conjugate (Starpharma Holdings)

N/A

Report date: 2025/01/19 10:50:28

Base Information

Drug Nametargeted DEP-trastuzumab conjugate (Starpharma Holdings)

Drug Alias Nametargeted DEP-Herceptin conjugate (DEP technology, ovarian cancer), Starpharma Holdings Ltd

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesStarpharma Pty Ltd

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

ATC CodeN/A